Previous Page  7 / 10 Next Page
Information
Show Menu
Previous Page 7 / 10 Next Page
Page Background

Page 44

Journal of Analytical & Bioanalytical Techniques | ISSN: 2155-9872 | Volume 9

World HPLC, Separation Techniques & Pharmacovigilance

World Analytical Chemistry & Mass Spectrometry

18

th

International Conference on

August 29-30, 2018 | Toronto, Canada

&

Differentiating

cannabis

products within the brands of the legalized adult use markets

W

ithin the framework of Bill C-45, Canada is positioned to become the global leader in the legal

cannabis

economy and

global exporter. The enactment of this Canadian Cannabis Act provides legal access to marijuana and to control and

regulate its production, distribution and sale. The primary objective of Health Canada’s regulatory policy bears stringencies

with respect to public health and safety and strict requirements for quality assurance, record keeping and mandatory testing

by 3

rd

party laboratories for product contamination. This opens an opportunity for advancing analytical development for

cannabis

metabolite profiling of active natural products and bleeds through to the accurate quantitative reporting of pesticides,

mycotoxins and heavy metalloids that serve regulatory audit to clear products for sale. A complete LC-MS/MS workflow is

described to quantitate 14 cannabinoids and screen for over 40 terpenoids to fingerprint various top

cannabis

dried flower

brands from the large enterprise-producers in a method that is delivered in under 15 mins of analytical run time using a dual

ESI and APCI ionization strategy. A wide linear dynamic range of 0.03 to 90% measurement (104 orders LDR) of cannabinoid

per LC-MS injection can be reported to provide a more accurate view for product labeling and dosing recommendations.

Terpene expression and metabolite measurement in plant cultivars are becoming less challenging with newly identified

terpene synthases and availability of new mono-terpenes and sesquiterpene standards. It is of high interest for results of these

metabolite profiling experiments to be correlated with plant cultivation parameters to achieve quality control and strengthen

the consumer's experience with a brand of

cannabis

and differentiate products for retail. Furthermore, pesticide residue analysis

in cannabis flower and oil formulations has been developed to meet the reporting requirements of Health Canada’s banned

pest control ingredients list. With UHPLC linked tandem mass analysis covering all of the 96 banned pesticides except for 11

compounds best suited by GC separation, it is possible to achieve a validated

cannabis

product certificate of analysis for issuance

to

cannabis

licensed producers in rapid turn-around. Analytical method details include LC separation using the Raptor Restek

Column, Raptor Biphenyl and newly available mixtures of pesticide standards to meet the Canadian Pest Management Agency’s

list of required pesticide maximum residual levels (down to 10 ppb in most cases). The addition of mycotoxins and other

organo-contaminants can also be inserted into our methods with the use of optimized Scheduled MRM mass spec scanning

techniques. The assembly of all the potency and ingredients data collection possible can provide information to consumers and

track benefits to the

cannabis

producers stride to bring powerful brands to the global

cannabis

market.

Biography

Brigitte Simons is a business development executive in support of leading-edge laboratory services and data management tools for the development of safe

cannabis. Bridging expertise within analytical science, pharma drug development and environmental testing – Brigitte have a professional track record for laboratory

testing instrumentation, software and sample contract design for the Canadian federal agencies, such as Canadian Food Inspection, Health Canada, Agriculture

Canada and Environment Canada. She spent over 6 years working in the Drug Toxicology and Analysis Division at Health Canada in a mass spectrometry facility

testing. She completed two post-doctoral fellowships at the Clinical Sciences Hospital of the National Heart, Blood & Lung Institute within the famous NIH campus

in Maryland, USA. Continuing on in lab specialties, Brigitte then joined SCIEX, a global instrumentation vendor for hardware and software for mass spectrometry.

With over 15 years experience with operating mass spectrometers, Brigitte managed Canadian federal and provincial government sales for full laboratory services,

covering clinical, forensics to product health and environmental safety. Prior to working abroad, Brigitte received her Ph.D. in Chemical Biology at the University of

Ottawa in a joint chemistry program with drug pharmacology at Health Canada.

bsimons@mscience.ca

Brigitte Simons

Molecular Science Corp., Canada

Brigitte Simons, J Anal Bioanal Tech 2018, Volume 9

DOI: 10.4172/2155-9872-C1-026